A 96-week efficacy and safety of BIC/FTC/TAF in ART-naïve HIV-1 infected patients in China
BIC/FTC/TAF demonstrated strong efficacy in patients with high baseline HIV-1 RNA and OIs, with no patient developing drug-related resistance mutations and minimal impact on metabolism, liver and renal function, supporting its use in broader populations as a first-line regimen.
Authors
- Linghua Li (ORCID: https://orcid.org/0000-0001-5711-8681)
- Quanmin Li (ORCID: https://orcid.org/0000-0001-8310-8823)
- Helei Hou (ORCID: https://orcid.org/0000-0001-8502-7461)
- Peishan Du
- Huolin Zhong
- Yun Lan (ORCID: https://orcid.org/0000-0002-9783-4268)
- Shiyun Lv (ORCID: https://orcid.org/0000-0001-8779-9430)
- Lijuan Chen (ORCID: https://orcid.org/0000-0002-6138-7873)
- Xiaoping Tang (ORCID: https://orcid.org/0000-0001-8365-3610)
- Jingliang Chen (ORCID: https://orcid.org/0000-0003-0719-7611)
- Xuemei Ling
Institutions
- Guangzhou Eighth People's Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Expert Review of Anti-infective Therapy
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1080/14787210.2025.2584555
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00